# This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

> **NCT06746311** · PHASE1 · COMPLETED · sponsor: **Suzhou HepaThera Biotech Co., Ltd.** · enrollment: 82 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** HT-101
- **DRUG:** HT-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06746311
- **Lead sponsor:** Suzhou HepaThera Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-22
- **Primary completion:** 2024-05-13
- **Final completion:** 2024-06-17
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2024-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06746311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06746311, "This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06746311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*